Resources
BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib
Leukemia & lymphoma, Vol. 62, Issue 6, Pages 1528-1531, 2021
PMID: 33478278
Mutations in the BCR-ABL1 kinase domain (BCR-ABL1 KD) is one of the most common determinants of tyrosine kinase inhibitor (TKI) resistance in patients with chronic myelogenous leukemia (CML) [1].
https://www.ncbi.nlm.nih.gov/pubmed/33478278
Considering Genomic Research?
Company
Resources
Research
- Tumor Microenvironment Solutions
- Immune Profiling Services
- NGS Services
- BioFX Bioinformatics Services
- Antibody Discovery Services
Diagnostics
Contact
2024 © MedGenome • All Rights Reserved